Finch Lindsey A, Levy Morgan S, Thiele Amanda, Jeudin Patricia, Huang Marilyn
Department of Obstetrics, Gynecology, and Reproductive Sciences, Jackson Memorial Hospital, Miami, FL, United States.
Department of Medical Education, University of Miami Miller School of Medicine, Miami, FL, United States.
Front Oncol. 2024 Mar 28;14:1359160. doi: 10.3389/fonc.2024.1359160. eCollection 2024.
The primary objective of this study was to evaluate patients' knowledge regarding HPV vaccination and vaccine uptake in a diverse patient population. The secondary objective was to evaluate factors influencing the decision to vaccinate, potential barriers to vaccination, and to assess whether HPV vaccines were offered to or discussed with eligible patients in a safety net Obstetrics and Gynecology (Ob/Gyn) clinic.
A 28-item survey was developed using Likert scale survey questions to assess patient agreement with statements regarding HPV and the vaccine. The surveys were administered to patients in the Ob/Gyn outpatient clinics from May 2021 through September 2022. Additionally, pharmacy data were reviewed and chart review was performed as a quality improvement initiative to assess the impact of expanded HPV vaccine eligibility to patients with private insurance on vaccine uptake. Descriptive statistics were performed.
304 patients completed surveys from May 2021 through September 2022. The median age of respondents was 32 (range 18-80). 16 (5%) were Non-Hispanic White, 124 (41%) were Hispanic White, 58 (19%) were Non-Hispanic Black, 6 (2%) were Hispanic Black, 29 (9.5%) were Haitian, 44 (14%) were Hispanic Other, 7 (2%) were Non-Hispanic Other, 20 (6.6%) did not respond. 45 (14%) patients were uninsured. Many patients (62%) reported that a physician had never discussed HPV vaccination with them. Seventy nine percent of patients reported they had never received the HPV vaccine, and 69% of patients reported that lack of a medical provider recommendation was a major barrier. Among patients to whom HPV vaccination had been recommended, 57% reported that the vaccine was not available the same day in clinic.
Our study demonstrated that many patients never had a provider discuss HPV vaccination with them and never received the HPV vaccine. Additionally, amongst those who did initiate HPV vaccination, completion of the series remains a key barrier. Ensuring that providers discuss HPV vaccination and that patients receive HPV vaccines, along with expanding access to and convenience of HPV vaccination are critical aspects of preventing cervical cancer.
本研究的主要目的是评估不同患者群体对人乳头瘤病毒(HPV)疫苗接种的认知及疫苗接种率。次要目的是评估影响接种决策的因素、接种的潜在障碍,并评估在一家安全网妇产科诊所中,是否向符合条件的患者提供了HPV疫苗或与他们讨论过该疫苗。
采用李克特量表式调查问题设计了一份包含28个条目的调查问卷,以评估患者对有关HPV及疫苗的陈述的认同程度。这些调查问卷于2021年5月至2022年9月期间在妇产科门诊分发给患者。此外,作为一项质量改进举措,对药房数据进行了审查,并进行了病历审查,以评估扩大HPV疫苗对有私人保险的患者的适用范围对疫苗接种率的影响。进行了描述性统计分析。
2021年5月至2022年9月期间,304名患者完成了调查。受访者的年龄中位数为32岁(范围为18 - 80岁)。16人(5%)为非西班牙裔白人,124人(41%)为西班牙裔白人,58人(19%)为非西班牙裔黑人,6人(2%)为西班牙裔黑人,29人(9.5%)为海地人,44人(14%)为其他西班牙裔,7人(2%)为其他非西班牙裔,20人(6.6%)未作答。45名(14%)患者没有保险。许多患者(62%)报告称医生从未与他们讨论过HPV疫苗接种问题。79%的患者报告他们从未接种过HPV疫苗,69%的患者表示缺乏医疗服务提供者的推荐是一个主要障碍。在被推荐接种HPV疫苗的患者中,57%报告称在诊所当天无法获得该疫苗。
我们的研究表明,许多患者从未有医疗服务提供者与他们讨论过HPV疫苗接种问题,也从未接种过HPV疫苗。此外,在那些开始接种HPV疫苗的患者中,完成整个接种系列仍然是一个关键障碍。确保医疗服务提供者讨论HPV疫苗接种问题、患者能够接种HPV疫苗,以及扩大HPV疫苗接种的可及性和便利性,是预防宫颈癌的关键方面。